Company profile for Immunitas Therapeutics

Immunitas Therapeutics

NEW Drugs in Dev: 1

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

Contact Supplier

Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

Contact Supplier

pharmacompass-1-m-2026-04-20

Contact Supplier

PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

Contact Supplier

Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

Contact Supplier

pharmacompass-2-m-2026-04-20

Contact Supplier

VIRTUAL BOOTH
CONTACT DETAILS
Google Map, LinkedIn, Emails...

DIGITAL CONTENT

14 News #PharmaBuzz

media
14 News #PharmaBuzz

DEVELOPMENTS

6 Drugs in Development

6 Drugs in Development

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Immunitas is an immuno-oncology therapeutics company advancing multiple programs to the clinic. Immunitas’ programs are derived from a cross-functional, highly integrated, single cell genomics platform that enables rapid target identification and validation in parallel with antibody discovery and engineering. IMT-009, a first-in-class T & NK cell modulator targeting CD161, is being developed for the treatment of solid tumors...

Immunitas is an immuno-oncology therapeutics company advancing multiple programs to the clinic. Immunitas’ programs are derived from a cross-functional, highly integrated, single cell genomics platform that enables rapid target identification and validation in parallel with antibody discovery and engineering. IMT-009, a first-in-class T & NK cell modulator targeting CD161, is being developed for the treatment of solid tumors and hematological malignancies. The company was founded with leading scientists from Dana Farber, MGH, the Broad, and MIT. In 2019, Immunitas raised a $39M Series

AMWC Asia-TDACAMWC Asia-TDAC

Not Confirmed

Not Confirmed

01-03 May, 2026

Taipei International Convention Center,Taipei
ArvoArvo

Not Confirmed

Not Confirmed

03-07 May, 2026

Denver, Colorado.U.S.A
AOCS Annual MeetingAOCS Annual Meeting

Not Confirmed

Not Confirmed

03-06 May, 2026

Louisiana, U.S.A

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown

United_States_of_America Flag

Country

Country

U.S.A

Address

Address

830 Winter St., 2nd floor Waltham, MA 02451

Telephone

Telephone

Email

enquiries@pharmacompass.com

Client Website

Website

https://www.immunitastx.com/

Linkedin

https://www.linkedin.com/company/immunitas/

youtube

YouTube

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

Immunitas Therapeutics Showcases IMT-009 Monotherapy And Combo

18 Mar 2026

// PR NEWSWIRE

Immunitas Presents IMT-380 Preclinical Data at FASEB

30 Jul 2025

// PR NEWSWIRE

Immunitas Therapeutics Presents Data at the AACR 2024 Annual Meeting

08 Apr 2024

// PR NEWSWIRE

Immunitas to Present Preclinical Data Supporting Combination of IMT-009

05 Mar 2024

// PR NEWSWIRE

Immunitas Appoints Annalisa D'Andrea, Ph.D., as Chief Scientific Officer

18 Jan 2024

// PR NEWSWIRE

Immunitas Therapeutics Announces Appointment of James Wooldridge as CMO

04 Dec 2023

// PR NEWSWIRE

Drugs in Development

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

Market Place

Home

Menu

Post Enquiry

Market Place

Search